#

+1 (917) 893 7512

  • #
  • #
  • #
#

Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)

Publish Date:Nov 2016
No. of Pages:58

Format : Adobe Reader (PDF) Instant delivery

US$ 800.00

Scope of the Report

The report entitled “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)”, provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share by products.

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global biosimilar market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies of the companies.

Company Coverage

Sandoz
Amgen
Celltrion
Pfizer

Executive Summary

Majority of biosimilars are in pipeline as most of the major biologics have either already expired or are about to lose their patent in the next two years which act as a major driving force for the biosimilar market. Four major biologics namely Humira, Enbrel, Remicade and Infliximab patents are set to expire in December 2016, incentivizes a large number of companies to enter into biosimilar market.

The biosimilar market is in its early stages, but is expected to grow in the next five years. The global biosimilar market is supported by various growth drivers such as growing pressure to curtail healthcare expenditure, patent expiries of major biopharmaceuticals, rising chronic disease among aging population and positive outcomes in ongoing clinical trials etc. Yet the market faces some challenges, such as restrict entry of new players, the complexity of manufacturing biosimilars and clinical limitations including patient recruitment obstacles.


Tags :

1. Executive Summary

2. Introduction

2.1 Overview of Pharmaceutical Industry
2.2 Overview of Biologics
2.2.1 Difference between Chemical Drugs Vs 1st Gen Vs 2nd Gen Biologics
2.2.2 Methods of Biologics Manufacturing 
2.2.3 Top 5 Biologics Drugs 
2.3 Overview of Biosimilars
2.3.1 Difference between Biosimilars and Generics 


3. Global Market Analysis
3.1 Global Pharmaceutical Market Analysis
3.1.1 Global Pharmaceutical Market by Value 
3.1.2 Global Pharmaceutical Sales: Biotech Vs Conventional Technology

3.2 Global Biologics Market Analysis
3.2.1 Global Biologics Market by Value
3.2.2 Global Biologics Market Share by Products

3.3 Global Biosimilar Market Analysis
3.3.1 Global Biosimilar Market by Value 
3.3.2 Major Biosimilars in the Pipeline

4. Market Dynamics

4.1 Growth Drivers
4.1.1 Growing Pressure to Curtail Healthcare Expenditure
4.1.2 Patent Expiries of Major Biopharmaceuticals 
4.1.3 Positive Outcomes in Ongoing Clinical Trials
4.1.4 Rising Demand for Biosimilars in Therapeutic Application 
4.1.5 Rising Chronic Disease among Aging Population

4.2 Challenges
4.2.1 Restrict Entry of New Players
4.2.2 Complexity of Expertise
4.2.3 Regulatory Challenges
4.2.4 Market Penetration Issue of Orphan Biosimilars
4.2.5 Clinical Limitations Including Patient Recruitment Obstacles

4.3 Market Trends
4.3.1 Emergence of New Market Participants
4.3.2 Inclusion of Drug Delivery Device
4.3.3 Uberization of Healthcare Industry 
4.3.4 Increasing Use of Single-Use Technology

5. Competitive Landscape

5.1 Global Biologics Market Sales by Drugs 

6. Company Profiling

6.1 Sandoz
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy

6.2 Amgen
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy

6.3 Celltrion
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy

6.4 Pfizer
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
Table 1: Chemical Drugs Vs 1st Generation Biologics Vs 2nd Generation Biologics
Figure 1: Biologics Manufacturing Method
Table 2: Top 5 Biologics Drugs
Table 3: US Approved Biosimilars
Table 4: Biosimilars Vs Generics 
Figure 2: Global Pharmaceutical Market by Value; 2015-2020E (US$ Billion) 
Figure 3: Global Pharmaceutical Sales- Biotech Vs Conventional Technology;2010-2015
Figure 4: Global Biologics Market by Value; 2010-2015 (US$ Billion)
Figure 5: Global Biologics Market by Value; 2016-2020E (US$ Billion) 
Figure 6: Global Biologics Market Share by Products; 2015
Figure 7: Global Biosimilar Market by Value; 2015-2020E (US$ Billion)
Table 5: Biosimilars in the Pipeline
Figure 8: Global Health Expenditure (% of Total GDP); 2010-2014
Table 6: Leading Biologic Products with Patent Expiries; 2014-2020
Figure 9: Global Aging Population; 2000-2015 (Million)
Table 7: Countries with Specific Biosimilar Guidelines
Figure 10: Global Biologics Market Sales by Drugs; 2015
Table 8: Sandoz Major Biosimilar Pipeline
Figure 11: Sandoz Revenue; 2010-2015 (US$ Billion)
Figure 12: Sandoz Revenue by Segment; 2015
Table 9: Amgen Major Biosimilar Pipeline
Table 10: Celltrion Major Biosimilar Pipeline
Figure 15: Celltrion Revenue; 2012-2015 (US$ Billion)
Table 11: Pfizer Major Biosimilar Pipeline
Figure 16: Pfizer Revenue; 2012-2015 (US$ Billion)
Figure 17: Pfizer Revenue by Geography; 2015